Your session is about to expire
← Back to Search
Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine for Brain Tumor
Study Summary
This trial is testing whether two PET imaging agents can better predict tumor response and overall survival than MRI in patients with high-grade brain tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have had allergic reactions to radiopharmaceuticals in the past. The decision to enroll you in the study if you have other allergies or autoimmune diseases will be made by the doctor in charge.My tumor cannot be removed surgically, so I had a biopsy instead.My scans suggest I have a high-grade brain tumor, awaiting confirmation.I do not have severe brain symptoms like sudden pupil changes, quick muscle weakness, or fast drops in alertness.I need anesthesia for PET scans.I have a high-grade brain tumor and will get chemoradiation. My surgery didn’t remove all of it, leaving a part larger than 1 cm.I have a high-grade brain tumor and might have a recurrence or treatment side effect within 6 months after chemoradiation.My recent lab tests are within the required range for the imaging procedure.I am 18 years old or older.You are too scared or uncomfortable in small, enclosed spaces to have a PET scan.
- Group 1: All Enrolled participants
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the total number of participants in this clinical research experiment?
"Affirmative. Records present on clinicaltrials.gov demonstrate that this medical trial is currently enlisting individuals; it was initially advertised in September 24th 2018, and the details were most recently updated October 6th 2022. The study demands 30 participants from a single location."
Are any new participants still eligible for this investigation?
"Yes, the current data on clinicaltrials.gov shows that this experiment is actively recruiting participants. It was initially posted in September 2018 and revised most recently in October 2022, with a need for 30 individuals across one medical centre."
Are there any records of experiments in which the imaging techniques [18F]FLT and [18F]Fluciclovine have been utilized together?
"At the moment, 4 active clinical trials are researching Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine with zero currently in Phase 3. These studies have been established across three different locations, one of which is Pittsburgh, Pennsylvania."
Is this the inaugural iteration of this particular clinical research?
"Since 2018, Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine have been investigated by Blue Earth Diagnostics. After the initial study with 30 participants in 2018, Phase 2 drug approval was granted for this product. Currently, there are 4 active studies on this topic taking place across 3 cities and 1 country."
Has the US Food and Drug Administration granted approval for Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine?
"Considering the lack of data validating its efficacy, Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine have been assigned a score of 2 on Power's safety scale."
Share this study with friends
Copy Link
Messenger